MacLennan G T, Bostwick D G
Division of Anatomic Pathology, Mayo Clinic, Rochester, MN 55905, USA.
Urology. 1995 Jul;46(1):27-30. doi: 10.1016/S0090-4295(99)80153-8.
Microvessel density (MVD) is a significant prognostic factor in many cancers, but its importance has not been evaluated in renal cell carcinoma. The objectives of this study were: (1) to determine the relationship of MVD in renal cell carcinoma to clinical stage, pathologic stage, histologic type, and tumor grade, and (2) to evaluate the role of MVD as a predictor of cancer-specific survival.
We reviewed the clinical and pathologic findings from 97 consecutive patients 60 years of age and younger with renal cell carcinoma treated at the Mayo Clinic between 1980 and 1982 by radical nephrectomy. Mean follow-up was 7.5 years, and 44 patients (45%) died of renal cell carcinoma. MVD was evaluated immunohistochemically using the labeled streptavidin-biotin-peroxidase method with a monoclonal antibody directed against factor VIII-related antigen. The area of highest MVD within the tumor was selected for review without knowledge of the patient's clinical parameters, and the number of vessels in an x400 field (0.1855 mm2) was counted.
Mean MVD was 741.2 vessels/mm2 (standard deviation, 394.3; range, 21.6 to 1078.2). In 49 cases (51%), there were greater than 1,000 vessels/mm2, forming a syncytium that precluded accurate vessel counting. In these cases, we used a value of 1,078 vessels/mm2 for calculations, corresponding to 200 vessels per x400 field. MVD was higher in clear cell than in non-clear cell carcinoma (811.2 versus 529.2 vessel/mm2, respectively; P = 0.007). There was no correlation of MVD and clinical stage, pathologic stage, tumor grade, of cancer-specific survival (all P > 0.05).
MVD is higher in the clear cell pattern of renal cell carcinoma than in non-clear cell patterns. MVD does not correlate with clinical stage, pathologic stage, or grade, and MVD has no predictive value for cancer-specific survival.
微血管密度(MVD)是许多癌症的重要预后因素,但在肾细胞癌中其重要性尚未得到评估。本研究的目的是:(1)确定肾细胞癌中MVD与临床分期、病理分期、组织学类型和肿瘤分级之间的关系,以及(2)评估MVD作为癌症特异性生存预测指标的作用。
我们回顾了1980年至1982年间在梅奥诊所接受根治性肾切除术治疗的97例60岁及以下肾细胞癌患者的临床和病理资料。平均随访时间为7.5年,44例(45%)患者死于肾细胞癌。采用标记链霉亲和素-生物素-过氧化物酶法,用抗VIII因子相关抗原的单克隆抗体对MVD进行免疫组化评估。在不了解患者临床参数的情况下,选择肿瘤内MVD最高的区域进行观察,并在×400视野(0.1855平方毫米)内计数血管数量。
平均MVD为741.2条血管/平方毫米(标准差为394.3;范围为21.6至1078.2)。49例(51%)患者的MVD大于1000条血管/平方毫米,形成一个难以准确计数血管的合体细胞。在这些病例中,我们使用1078条血管/平方毫米的值进行计算,相当于每个×400视野中有200条血管。透明细胞癌的MVD高于非透明细胞癌(分别为811.2条血管/平方毫米和529.2条血管/平方毫米;P = 0.007)。MVD与临床分期、病理分期、肿瘤分级或癌症特异性生存均无相关性(所有P > 0.05)。
肾细胞癌透明细胞型的MVD高于非透明细胞型。MVD与临床分期、病理分期或分级无关,且对癌症特异性生存无预测价值。